[go: up one dir, main page]

YU36900A - Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendan - Google Patents

Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendan

Info

Publication number
YU36900A
YU36900A YU36900A YU36900A YU36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A YU 36900 A YU36900 A YU 36900A
Authority
YU
Yugoslavia
Prior art keywords
levosimendan
transmucosal
preparation
treatment
source
Prior art date
Application number
YU36900A
Other languages
English (en)
Inventor
Kauko Kurkela
Martti Marvola
Ilkka Larma
Raimo Virtanen
Marianne Karlsson
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of YU36900A publication Critical patent/YU36900A/sh
Publication of RS49889B publication Critical patent/RS49889B/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0034Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Luminescent Compositions (AREA)
  • Paper (AREA)
  • Air Bags (AREA)

Abstract

Opisan je intraoralni ili intranazalni transmukozni preparat koji sadrži levosimendan ili njegovu farmaceutski prihvatljivu so kao aktivnu komponentu. Ovaj preparat je bukalni, sublingualni ili sinuidalni transmukozni preparat. Opisana je upotreba ovog preparata za proizvodnju medikamenta - leka za transmukoznu primenu oralne ili nazalne mukoze za tretiranje srčanog udara.[Described is a method of administering transmucosally, particularly to oral or nasal mucosa, levosimendan or a pharmaceutically acceptable salt thereof to a patient. The method comprises contacting an intact mucous membrane with a source of levosimendan, and maintaining said source in contact with said mucous membrane for a sufficient time period to deliver levosimendan to the patient. Transmucosal preparations of levosimendan are also described. Levosimendan is useful in the treatment of heart failure.
YUP-369/00A 1997-12-19 1998-12-11 Intraoralni ili intranazalni transmukozni preparat koji sadrži levosimendan RS49889B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI974578A FI974578L (fi) 1997-12-19 1997-12-19 Menetelmä levosimendaanin antamiseksi

Publications (2)

Publication Number Publication Date
YU36900A true YU36900A (sh) 2003-02-28
RS49889B RS49889B (sr) 2008-08-07

Family

ID=8550178

Country Status (26)

Country Link
US (1) US6399610B1 (sh)
EP (1) EP1052973B1 (sh)
JP (1) JP2001526205A (sh)
KR (1) KR100753689B1 (sh)
AT (1) ATE215358T1 (sh)
AU (1) AU738082B2 (sh)
BR (1) BR9813641A (sh)
CA (1) CA2313618C (sh)
CZ (1) CZ296693B6 (sh)
DE (1) DE69804678T2 (sh)
DK (1) DK1052973T3 (sh)
EA (1) EA002197B1 (sh)
EE (1) EE04330B1 (sh)
ES (1) ES2175827T3 (sh)
FI (1) FI974578L (sh)
HR (1) HRP20000400B1 (sh)
HU (1) HU226736B1 (sh)
IL (1) IL136415A (sh)
NO (1) NO320050B1 (sh)
NZ (1) NZ504806A (sh)
PL (1) PL191868B1 (sh)
PT (1) PT1052973E (sh)
RS (1) RS49889B (sh)
SK (1) SK284838B6 (sh)
WO (1) WO1999032081A1 (sh)
ZA (1) ZA9811405B (sh)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI980901A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI20002755A0 (fi) 2000-12-15 2000-12-15 Orion Yhtymae Oyj Menetelmä erektiilin dysfunktion hoitamiseen
CN100428937C (zh) * 2003-10-30 2008-10-29 北京海合天科技开发有限公司 左西孟旦冷冻干燥组合物
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
WO2006089082A2 (en) * 2005-02-17 2006-08-24 Velcera Pharmaceuticals Transmucosal administration of drug compositions for treating and preventing disorders in animals
US20070032557A1 (en) * 2005-02-18 2007-02-08 Matti Kivikko Method for administering levosimendan
WO2007096906A2 (en) * 2006-02-27 2007-08-30 Panacea Biotec Ltd. Novel buccoadhesive compositions and process of preparation thereof
JP2010504931A (ja) * 2006-09-27 2010-02-18 ニコノヴァム エービー 指向性の使用
US11523986B2 (en) * 2019-03-22 2022-12-13 Dbbh, Llc Intranasally administered antihistamines and uses thereof
WO2021001601A1 (en) * 2019-07-01 2021-01-07 Orion Corporation Methods for administering (r)-n-[4-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)phenyl]acetamide
US11969424B2 (en) 2019-12-16 2024-04-30 Tenax Therapeutics, Inc. Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5688520A (en) * 1995-03-29 1997-11-18 Minnesota Mining And Manufacturing Company Transmucosal delivery of melatonin for prevention of migraine
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan

Also Published As

Publication number Publication date
IL136415A0 (en) 2001-06-14
NO20003059D0 (no) 2000-06-14
HU226736B1 (en) 2009-08-28
DE69804678D1 (de) 2002-05-08
ES2175827T3 (es) 2002-11-16
US6399610B1 (en) 2002-06-04
FI974578A0 (fi) 1997-12-19
ATE215358T1 (de) 2002-04-15
NZ504806A (en) 2001-09-28
SK9062000A3 (en) 2000-12-11
WO1999032081A1 (en) 1999-07-01
PL341202A1 (en) 2001-03-26
IL136415A (en) 2005-03-20
HRP20000400A2 (en) 2000-12-31
PL191868B1 (pl) 2006-07-31
KR20010033368A (ko) 2001-04-25
FI974578A7 (fi) 1999-06-20
EP1052973B1 (en) 2002-04-03
NO20003059L (no) 2000-06-14
HUP0100452A3 (en) 2002-03-28
HRP20000400B1 (hr) 2009-06-30
FI974578L (fi) 1999-06-20
CZ296693B6 (cs) 2006-05-17
PT1052973E (pt) 2002-09-30
AU738082B2 (en) 2001-09-06
SK284838B6 (sk) 2005-12-01
RS49889B (sr) 2008-08-07
KR100753689B1 (ko) 2007-08-30
NO320050B1 (no) 2005-10-17
CA2313618C (en) 2008-02-05
CA2313618A1 (en) 1999-07-01
DE69804678T2 (de) 2002-11-21
JP2001526205A (ja) 2001-12-18
CZ20002155A3 (cs) 2000-11-15
EP1052973A1 (en) 2000-11-22
AU1565699A (en) 1999-07-12
BR9813641A (pt) 2000-10-17
HUP0100452A2 (hu) 2002-02-28
EA002197B1 (ru) 2002-02-28
EE04330B1 (et) 2004-08-16
EA200000686A1 (ru) 2000-12-25
ZA9811405B (en) 1999-06-11
DK1052973T3 (da) 2002-04-29
EE200000368A (et) 2001-10-15

Similar Documents

Publication Publication Date Title
ATE468845T2 (de) Bukkale transmukosale arzneidarreichung unter verwendung einer festen lösung
DE69916486D1 (de) Nicotin enthaltende pharmazeutische zusammensetzungen mit schneller transmukosaler absorption
KR970703151A (ko) 알렌드로네이트의 경구 액상 제형(Oral liquid alendronate formulations)
DK1471890T3 (da) Farmaceutisk doseringsform til mukös afgivelse
CA2569674A1 (en) Sublingual buccal effervescent
MY127422A (en) Low dose entecavir formulation and use
JP5897509B2 (ja) 口内で使用される窪みのある接着性口内パッチ
YU36900A (sh) Intraoralni i intranazalni transmukozni preparat koji sadrži levosimendan
MX2010010839A (es) Composicion para la higiene oral y aparato y metodo.
RU2001126555A (ru) Составы фармацевтической жевательной резинки
JP2008542299A5 (sh)
WO2000056344A1 (fr) Salive artificielle
RU92011840A (ru) Состав для профилактики заболеваний пародонта и слизистой оболочки полости рта "биостом"
WO2008111384A1 (ja) 上皮改善剤
EP0315332B1 (en) Antitussive liquid compositions containing phenol
JP2005518435A5 (sh)
UA37278C2 (uk) Протикашльова фармацевтична композиція для перорального введення
WO2001074396A8 (en) Composition and method for promoting oral health
Bhowmik et al. Buccal drug delivery system-a novel drug delivery system
Yun et al. Pharmaceutical devices for oral cavity-based local and systemic drug delivery
DK1448184T3 (da) Anvendelse af propionyl-L-carnitin eller et af dets farmakologisk acceptable salte til fremstilling af en medicin til behandling af Peyronies sygdom
Chauhan et al. Cultural Practices involving Teeth and Oro-facial Soft Tissues–A Review
MD1469G2 (ro) Metodă de tratament al şocului combustional
KR20060115092A (ko) 니코틴을 함유하는 구강청정제